Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Alan Meds vs Aquivia Health

Alan Meds
Graded #98

Lower grade

vs+1.1000000000000085
Aquivia Health
Graded #81

Higher grade

The verdict

Aquivia Health takes it — 72.2/100 to 71.1/100, but only just.

Aquivia Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Aquivia Health is a clinician-led, self-pay telehealth platform offering compounded GLP-1 therapy with the option to step up to branded Ozempic or Zepbound — an unusual side-by-side most compounded… Alan Meds is close behind and may still be the better fit — see the factor split below.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueAquivia Health +14
72
86
Dose & formulationAquivia Health +10
75
85
Clinical oversightAlan Meds +18
82
64
Labs & monitoringEven
53
53
FulfillmentAlan Meds +7
78
71
Contract termsEven
55
55
Alan Meds · left barAquivia Health · right bar

The numbers

MetricAlan MedsAquivia Health
WeighScore71.1/10072.2/100
GradeCC
Scorecard rank#98#81
Semaglutide$158/mo (compounded)$149/mo
Tirzepatide$295/mo (compounded)$179/mo
Coverage46 statesCoverage not published
Brand-name accessCompounded onlyYes
Oral / sublingualYesInjection only
Alan Meds

Graded #98 · C

Strengths

  • Aggressively low monthly pricing
  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access
  • Multiple administration formats

Where it loses points

  • Limited public information on program details
Aquivia Health

Graded #81 · C

Strengths

  • Clinical care provided by Open Loop Healthcare Partners, PC — a reused, verified MSO network
  • Named leadership: Steven Bishop MD (CMO), Phillip Gray PharmD (Chief Pharmacist), Tom Foster (President)
  • Itemized public pricing: compounded semaglutide $149/mo, tirzepatide $179/mo, Ozempic $1,299, Zepbound $1,399
  • Both compounded and branded GLP-1s offered side by side — unusual for a compounded provider
  • Self-pay model with no insurance required and no separate consultation fee

Where it loses points

  • No public list of states served — you must complete intake to learn if your state qualifies
  • No named 503A compounding pharmacy partner, limiting licensure verification
  • No LegitScript, PCAB, or BBB trust badges visible
  • Brand confusion: site schema names 'CatalystMD' while the customer-facing brand is Aquivia Health
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard